[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Synbiotic Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100624304","ivs-1-probiotic-intervention-targeting-biological-aging-in-midlife-adults-100624304",false,"NCT07407894","iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults","VITAL-Age Trial (iVS-1 Investigation for Targeting Aging and Longevity)","VITAL","Inclusion Criteria:\n\n* Aged 40-75 years.\n* BMI: 20-34.9 kg\u002Fm².\n* Able and willing to sign informed consent and participate for the study duration.\n\nExclusion Criteria:\n\n* Chronic disease history (liver, kidney, heart).\n* Current pregnancy and\u002For lactating.\n* Colonoscopy and\u002For its preparation within 4 weeks of screening.\n* Those who intend to have children during study period.\n* Current probiotic, prebiotics and\u002For metabolic-altering supplement use.\n* Those who are unable to cooperate with investigators and testing.\n* Known history of cancer and\u002For ongoing cancer treatments.\n* Abuse of drugs, alcohol, tobacco, nicotine and other substances.\n* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.\n* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.\n* Type 1 or 2 diabetes mellitus.\n* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.\n* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.\n* Significant weight loss (\\>20%) in prior one month.\n* Conditions affecting safety or outcome integrity.",true,"ALL","40 Years","75 Years",{"count":22,"type":23},80,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.",[29,30],"Healthy Aging","Anti Aging",[32,33,34,35,36,37,38],"Bifidobacterium adolescentis","iVS-1","Aging","Geroscience","Gut Microbiome","Probiotic","Healthspan","RECRUITING","2026-04-21",{"date":42,"type":43},"2026-04-22","ACTUAL",{"date":45,"type":43},"2026-02-01",{"date":47,"type":23},"2027-01",{"name":49,"class":50},"Synbiotic Health","INDUSTRY",""]